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Drs.  Valerie  Askanas  and  King  Engel  have  made 
seminal contributions to our understanding and therapy 
of neuromuscular diseases over many decades and we are 
honored to contribute this article in appreciation of their 
accomplishments.
Neuroinflammation is a pathological hallmark of neurodegen-
erative diseases including amyotrophic lateral sclerosis (ALS), 
and is characterized by activated microglia at sites of neuronal 
injury. In ALS. neurons do not die alone; neuronal injury is non-
cell-autonomous and depends upon a well-orchestrated dialogue 
between motor neurons and microglia. Evidence from transgenic 
models expressing mutant superoxide dismutase 1 (SOD) suggests 
that the dialogue between motor neurons and microglia initially 
protects motor neurons. However, with increasing stress and in-
jury within motor neurons, induced by the presence of misfolded 
proteins such as mSOD1, mitochondrial function and axoplasmic 
flow are impaired and endoplasmic reticulum stress is induced; 
misfolded proteins themselves or alternate signals are released 
from motor neurons and activate microglia. Activated microglia, 
in turn, switch from anti-inflammatory and neuroprotective to 
proinflammatory and neurotoxic. Neurotoxic signaling from mo-
tor neurons promotes microglial release of reactive oxygen spe-
cies and pro-inflammatory cytokines further enhancing motor 
neuron stress and cell injury and initiating a self-propagating cy-
cle of motor neuron injury and cell death. A greater understand-
ing of how to restore the imbalance between neuroprotection and 
cytotoxicity will depend upon a greater understanding of the mo-
tor neuron-microglial dialogue.
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Our own efforts have focused on amyotrophic lateral 
sclerosis (ALS) and the role of neuroinflammation in the 
pathogenesis of ALS. This inexorably progressive neuro-
degenerative disease is characterized by selective loss of 
lower and upper motor neurons, resulting in varying de-
grees of atrophy and weakness in limb musculature, spas-
ticity, and compromised speech, swallowing, and breath-
ing. The presence of activated microglia, astrogliosis, and 
infiltrating  lymphocytes  accompanying  motor  neuron 
injury in ALS spinal cord tissue has raised the question 
as to whether motor neuron cell loss is dictated solely by 
intracellular events – cell-autonomous – or whether other 
cells may be involved. This question cannot be answered 
directly from human studies, but has been addressed in the 
transgenic mouse model of ALS overexpressing a human 
mutation of Cu2+Zn2+ superoxide dismutase (mSOD1) (1). 
In both human ALS and the transgenic mSOD1 mouse, 
there  is  evidence  of  neuroinflammation  with  increased 
microglial activation as well as increased CD4 and CD8 T 
cells and dendritic cells (2, 3). Expression of the mSOD1 
transgene in motor neurons alone is not sufficient to cause 
motor neuron injury (4). Further, expression solely in as-
trocytes or microglia does not lead to a motor neuron phe-
notype. Thus motor neurons do not die alone. To cause 
significant injury, mSOD1 must be expressed in motor 
neurons as well as surrounding cells. This non-cell au-
tonomy suggests a potential contribution of non-motor 
neuron cells such as microglia to motor neuron protection 
as well as motor neuron injury and cell death. 
Motor Neuron-Microglia Neuroprotective Signaling 
Motor  neurons  have  been  documented  to  promote 
microglia-mediated neuroprotection through at least two 
signals, fractalkine and CD200. The neuroprotective state 
of microglia characteristically releases anti-inflammatory 
cytokines  and  neurotrophic  factors  (Fig.  1).  Microglia 
are the only CNS cells that express the fractalkine recep-
tor (CX3CR1). Based on complementary expression of 
fractalkine (CX3CL1) on neurons and CX3CR1 on mi-
croglia, it had been proposed that neuroprotective signal-
ing from motor neuron to microglia might be mediated 
through this receptor. In vivo, CX3CR1 deficiency dys-
regulates microglial responses, resulting in neurotoxic-
ity. Following peripheral lipopolysaccharide injections, 
CX3CR1-/-  mice  showed  cell-autonomous  microglial 
neurotoxicity (5). Doubly transgenic mSOD/ CX3CR1-/- 
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mice  exhibited  more  extensive 
neuronal cell loss than CX3CR1+ 
littermate controls. Thus fractalk-
ine  release  from  motor  neurons 
enhances  neuroprotection,  and 
the loss of the fractalkine receptor 
on microglia enhances neurotox-
icity. Mice deficient for CD200, 
a  neuronal  glycoprotein  whose 
receptor,  CD200R,  is  expressed 
by all myeloid cells, show aber-
rant  microglial  physiology  in-
cluding morphological activation 
of microglia in the resting CNS 
and  accelerated  response  to  fa-
cial nerve transection (6). None 
of these attributes of altered mi-
croglial  function  are  observed 
in  CX3CR1-/-  mice,  indicating 
different  neuroprotective  path-
ways  for  CD200/CD200R  and 
CX3CL1/CX3CR1 in regulating 
microglia.
Microglia-Motor Neuron Cytotoxic Signaling
To help define the pathways for neurotoxic signal-
ing in the microglia-motor neuron dialogue, we employed 
motor neurons co-cultured with microglia activated by 
lipopolysaccharide  (LPS),  which  induced  a  proinflam-
matory M1 state in microglia, enhancing the production 
and release of NO and superoxide anion, and resulting 
in the formation of the extremely toxic compound per-
oxynitrite (8). This microglial proinflammatory state, in 
turn, led to motor neuron injury and cell death, mediated 
by reactive oxygen species and glutamate excitotoxicity. 
In the presence of increased NO, superoxide anion, and 
H2O2, extracellular glutamate interacting with the gluta-
mate receptor on motor neurons resulted in increased en-
try of calcium and initiated a cell death cascade. mSOD1 
microglia per se were found to be more activated than 
wild-type microglia, and produced and released more NO 
and superoxide anion than wild-type microglia, resulting 
in increased motor neuron cell death. Conversely, wild-
type microglia were demonstrated to have increased re-
lease of neurotrophic factors IGF-1 and BDNF It was not 
necessary for mSOD1 to be expressed solely in microglia 
since the addition of extracellular mSOD1G93A protein to 
wild-type microglia was able to induce morphological 
and functional activation similar to the effects of LPS, 
increasing  release  of  pro-inflammatory  cytokines  and 
free radicals (Zhao et al. 2010). Exogenous mSOD1G93A 
did not cause detectable direct killing of motoneurons 
alone.  However  when  motoneurons  were  co-cultured 
with microglia, the addition of extracellular mSOD1G93A 
caused motor neuron cell death. The addition of wild-
type mSOD1 protein to microglial-motor neuron cultures 
produced minimal motor neuron injury.
Microglial Receptors Mediating Cytotoxic Signaling 
CD14 is a pattern recognition receptor for misfolded 
proteins and mutations in, or oxidation of, SOD1 lead 
to misfolded proteins (9). We were able to demonstrate 
that mSOD1G93A was bound to CD14. CD14 blocking an-
tibodies attenuated the production of pro-inflammatory 
cytokines and free radicals and increased IGF-1 release 
from mSOD1G93A-treated microglia. When CD14-/- micro-
glia were substituted for wild-type microglia, motor neu-
ron injury and cell death were significantly attenuated. 
These in vitro studies are relevant to the in vivo state since 
expression of CD14 was significantly increased in spinal 
cord tissues of both ALS patients and mSOD1 mice (2, 3). 
Co-receptors for CD14 are the toll-like receptors TLR2 
and TLR4; and previous studies suggested that CD14 and 
TLR contribute to the inflammatory responses initiated 
by microglia (10). Upregulation of CD14 and TLR2 in 
phagocytes are common in neurodegenerative diseases 
including transgenic models of Alzheimer’s disease, Par-
kinson’s disease, as well as ALS. Alzheimer Aß fibrils 
bind to CD14 and activate microglia, and anti-CD14 strat-
egies reduce the neurotoxicity of Aß-stimulated micro-
glia (11). Additionally, chronic stimulation of the CD14/
TLR pathway by LPS was found to exacerbate disease in 
figure 1. Microglia- Innate immune Cells of the CNS help mediate the balance 
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ALS mice and TLR4 was necessary for LPS-sensitized 
hypoxic-ischemic neurodegeneration in vivo (12). In our 
studies microglia-mediated toxicity of motoneurons was 
attenuated with antibodies which blocked both TLR2 and 
TLR4. These data suggest that extracellular mSOD1G93A 
is  similar  to  LPS,  interacting  with  CD14,  which  then 
ligates TLR2  and TLR4,  activating  a  proinflammatory 
cascade, increasing release of NO and superoxide anion, 
and decreasing the release of protective neurotrophic fac-
tors. Microglial release of proinflammatory factors in vit-
ro leads to motor neuron injury and cell death. However, 
the addition of the cytokine IL-4 reversed LPS-induced 
and microglia-mediated motor neuron cytotoxicity; IL-4 
suppressed  nitric  oxide  and  superoxide  anion  release, 
enhanced release of IGF-1, and promoted motor neuron 
survival (13). These data suggest that IL-4 may provide 
a significant immunomodulatory signal, protecting motor 
neurons from microglia-mediated neurotoxicity by sup-
pressing the production and release of free radicals.
Motor Neuron-Microglia Cytotoxic Signaling - The role 
of mSOD1 
A  key  question  is  whether  any  evidence  demon-
strates that microglia can be activated by the release of 
mSOD1 protein from motor neurons. An elegant series 
of papers have addressed this question directly. Chrom-
ogranins, components of neurosecretory vesicles, were 
documented to interact with mutant forms of superoxide 
dismutase but not with wild-type SOD1 (14). This inter-
action was confirmed by yeast two-hybrid screen and by 
co-immunoprecipitation assays using either lysates from 
Neuro2a  cells  coexpressing  chromogranins  and  SOD1 
mutants or lysates from spinal cord of ALS mice. Con-
focal and immunoelectron microscopy revealed a partial 
colocalization of mutant SOD1 with chromogranins in 
spinal cord of ALS mice. Mutant SOD1 was also found 
in immuno-isolated trans-Golgi network and in micro-
some preparations, suggesting that it could be secreted. 
Furthermore, chromogranins were demonstrated to act as 
chaperone-like proteins and promote secretion of SOD1 
mutant proteins. 
Motor Neuron- Microglia Cytotoxic Signaling - The role 
of OxidizedSOD1 
Recent evidence demonstrates that oxidation of WT 
SOD1 results in misfolded protein that may acquire the 
binding  and  toxic  properties  of  mSOD1,  suggesting  a 
possible shared pathway between sporadic and inherited 
ALS cases (15). Exposure of transfected Neuro2a cells 
expressing WT  or  amyotrophic  lateral  sclerosis-linked 
SOD1 species to H2O2 resulted in oxidized SOD1. West-
ern blot analysis of immunoprecipitates from cell lysates 
revealed that, like mutant SOD1, oxidized WT SOD1 was 
conjugated with poly-ubiquitin, interacted with Hsp70. 
and was co-immunoprecipitated with Chromogranin B. 
Treatment of microglial cells (line BV2) with either oxi-
dized WT SOD1 or mutant SOD1 recombinant proteins 
induced tumor necrosis factor-alpha and inducible nitric 
oxide  synthase.. These  results suggest  that WT SOD1 
may acquire binding and toxic properties of mutant forms 
of SOD1 through oxidative damage.
The over-expression of chromogranin in spinal cord 
neurons of mSOD1 transgenic mice resulted in signifi-
cantly increased misfolded SOD1 species, earlier disease 
onset,  and  enhanced  motor  neuron  degeneration  (16). 
These findings are of relevance to human ALS since the 
P413L variant of chromogranin B was noted to be present 
in 10% of ALS patients (n = 705) as compared to 4.5% in 
controls (n = 751), conferring a 2.2-fold greater relative 
risk to develop the disease (P < 0.0001), and was associ-
ated with an earlier age of onset by almost a decade in 
both sporadic ALS and familial ALS cases (17).
The evidence that mutant and oxidized SOD1 can 
be secreted from motor neurons may also be pertinent to 
sporadic cases of ALS; the presence of oxidized wild-type 
SOD1 in sporadic ALS spinal cord motor neurons was 
recently described (18). Oxidized wild-type SOD1 and 
mutant SOD1 share a conformational epitope not present 
in  normal  wild-type  SOD1,  and  this  common  epitope 
permitted the immunohistochemical demonstration of an 
aberrant wild-type misfolded SOD1 species present in 
motor neurons in the lumbosacral spinal cord of a sub-
set of human sporadic ALS (SALS) cases. SOD1 immu-
nopurified from this subset behaved similarly to familial 
ALS-linked mutant SOD1 and to recombinant, oxidized 
wild-type SOD1 in a model of axonal transport in vitro; 
wild-type SOD1 immunopurified from SALS tissues, ox-
idized wild-type SOD1, and familial ALS-linked mutant 
SOD1 all inhibited kinesin-based fast axonal transport 
whereas control wild-type SOD1 did not. Oxidative stress 
is one of the prominent findings in the CNS and periph-
eral circulation of ALS patients, and the demonstration of 
oxidized SOD1 in sporadic ALS motor neurons suggests 
an SOD1-dependent pathogenic mechanism common to 
FALS and SALS.
Microglia-Mediated Neuroprotection and Cytotoxicity 
in vivo 
To evaluate the effects of microglia in vivo, we used 
PU.1 knockout (PU.1−/−) mice that at birth lack macro-
phages, neutrophils, T- and B-cells, and microglia, and 
require bone marrow transplation for survival (19). As a 
result all parenchymal microglia are derived from the bone 
marrow transplants, and the microglia have the genotype 
of the donor bone marrow cells. When we transplanted The Microglial-Motoneuron dialogue in ALS
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PU.1−/−  mice  with  mSOD1G93A 
bone  marrow,  all  CNS  micro-
glia  were  mSOD1G93A  positive. 
However, we noted no clinical or 
pathological  evidence  of  motor 
neuron disease. Thus mSOD1G93A 
microglia  did  not  cause  motor 
neuron disease if mSOD1G93A was 
not expressed in motor neurons. 
We  then  crossed  PU.1−/−  mice 
with  mSOD1G93A  mice  to  pro-
duce  mSOD1G93A/PU.1−/− doubly 
transgenic mice, which expressed 
mSOD1G93A in motor neurons as 
well as astrocytes and other cell 
types,  and  still  required  a  bone 
marrow  transplant  for  survival. 
In these doubly transgenic mice 
the parenchymal microglia were 
derived  from  the  donor  trans-
plant.  mSOD1G93A/PU.1−/−  mice 
transplanted with wild-type bone 
marrow had wild-type microglia 
throughout  the  parenchyma,  while  mSOD1G93A/PU.1−/− 
mice  transplanted  with  mSOD1G93A  bone  marrow  had 
mSOD1G93A microglia throughout the parenchyma. The 
mSOD1G93A/PU.1−/−  transgenic  mice  with  mSOD1G93A 
parenchymal  microglia  died  considerably  earlier  and 
had greater motor neuron loss and shorter disease dura-
tion than the doubly transgenic mice with wild-type pa-
renchymal microglia (19). Thus the ability of activated 
mSOD1 microglia to induce motor neuron injury in vitro 
was comparable to the mSOD1 microglia-mediated mo-
tor neuron injury in vivo, and most likely resulted from 
microglial-mediated release of neurotoxic substances and 
decreased release of neuroprotective factors. Conversely 
wild-type  microglia  mediated  relative  neuroprotection 
both in vitro and in vivo.
Summary: the Relevance of Neuroinflammation to ALS 
Pathogenesis
The major themes in ALS pathogenesis are depict-
ed in Figure 2. Evidence from the mSOD1 transgenic 
mouse suggests that alterations in distal motor axons are 
among the earliest pathological changes in the pathogen-
esis of ALS, and the process is best explained as “dying 
back.” End-plate denervation is noted prior to the evi-
dence of ventral root or cell body loss, and prior to the 
appearance of activated microglia surrounding affected 
motor neurons (20). In ALS patients, mitochondrial al-
terations consisting of swelling and increased calcium 
are present in motor axon terminals at early stages (21). 
Thus alterations in synaptic function and axonal con-
nectivity  may  represent  early  and  critical  pathogenic 
events in ALS. Subsequent changes in axonal transport 
are also early events in ALS, impairing the transport of 
newly synthesized proteins and lipids and the clearance 
of damaged or misfolded proteins (22). A significant 
decrease in retrograde survival factors, including P-Trk 
(phospho-Trk) and P-Erk1/2, and an increase in retro-
grade stress factor signaling, including P-JNK (phos-
phorylated  c-Jun  N-terminal  kinase),  caspase-8,  and 
p75(NTR) cleavage fragment have been documented in 
the mSOD1 transgenic mouse (23). Thus a shift from 
survival-promoting to death-promoting retrograde sig-
naling may be a key step leading to neurodegeneration 
in ALS. This switch from survival-promoting to death-
promoting does not occur in mSOD1 motor neurons in 
vitro unless they are maintained on mSOD1 supporting 
cells. Thus, the evidence for non-cell autonomy necessi-
tates the conclusion that changes within the neuron itself 
are insufficient to cause motor neuron death, but require 
motor-neuron–microglia signaling at least at the level 
of the cell soma. Whether the axonal death-promoting 
signaling is directly responsible for triggering ER stress, 
which further exacerbates the unfolded protein response 
and activates caspases, is unclear. What is clear is that 
motor neuron ER stress is a prominent feature of mouse 
and human ALS, and enhances release of neurotoxic 
signals, including possibly mSOD itself. These signals 
activate  microglia  to  release  free  radicals  and  proin-
flammatory cytokines, and in turn, cause further motor 
neuron stress and initiate a self-propagating cytotoxic 
figure 2. Major themes in ALS pathogenesis.S.H. Appel et al.
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cascade. A  greater  understanding  of  the  bidirectional 
signaling  between  motor  neurons  and  microglia  may 
lead to therapies that can restore the imbalance between 
neuroprotection and cytotoxicity. 
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